Israel-based Mybiotics Pharma has signed an agreement with Ferring Holding to license the use of its MyCrobe technology, aimed at developing bacteria that benefit women’s health. MyCrobe has developed bacterial fermentation techniques based on the study of interactions between intestinal and central nervous system, and specifically on how bacterial flora influences interactions between those systems. Early studies on this topic have stressed the effects of bacterial flora on disorders such as autism, depression and obesity; additionally, they have proven that “good” bacteria have fairly low resistance to pathogens and other adverse events. Mybiotics’ scientists are using MyCrobe to introduce “good” and highly resistant bacteria into the intestine through food supplements or modified food.
(Source: Yahoo Finance)